Envelope C2-V3-C3-specific antibodies from HIV-1 infected patients from Angola correlate with neutralization activity in plasma

Poster presented at the 2015 Keystone Symposia Conference X5: HIV Vaccines. Banff, Alberta, Canada, 22-27 March 2015

"Development of immunogens that induce broadly neutralizing antibodies (bNAbs) is a major goal in HIV-1 vaccine field. Recently, we found that bNAbs can be elicited in Balb/c mice against HIV-2 by using a prime-boost vaccination strategy combining recombinant Vaccinia virus expressing a truncated form of the SU glycoprotein and a polypeptide comprising the C2, V3 and C3 envelope regions. We want to test the hypothesis that a similar vaccination strategy can also be effective for HIV-1. We also want to test the hypothesis that envelope glycoproteins derived from ancestral HIV-1 isolates from Angola may induce a broader neutralizing antibody response compared to envelope glycoproteins derived from contemporaneous isolates."